Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.24 USD | +3.14% | +2.18% | -44.55% |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Apr. 22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.55% | 2.76B | |
+2.43% | 42.75B | |
+47.70% | 41.61B | |
+12.06% | 41.34B | |
-8.83% | 26.59B | |
+6.65% | 25.49B | |
-22.87% | 18.12B | |
+30.41% | 12.24B | |
-2.05% | 11.76B | |
+9.21% | 11B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Sector Update: Health Care Stocks Stronger Late Afternoon